In the methods, it would be useful to have more detailed information about how the hospitals were approached (how and who was contacted). For the statistical analyses, coefficients of variations are mentioned in the text but there is little information as to these estimates (no table of results with the coefficients). Also, there are various methods to measure variation. The authors do not mention such methods, nor do they seem to apply them. Instead, it appears like the authors ran regressions on the prices of the products. I am not convinced that this is the most appropriate technique. We do not know the distribution of prices for each product, but the data may require some transformation prior to running regressions. I am concerned that the estimates may be biased. There is no mention of requesting/obtaining ethics approval for the study.
GENERAL COMMENTS
The intent of this paper is compelling yet the findings seem too narrow for a fulsome discussion of transparency in medical products and how a lack of transparency can impact variation in prices of the same product. I would recommend a larger contextual discussion of how the Dutch experience may translate into other jurisdictions. Also, what factors contribute to high prices that are not necessarily a result of information asymmetry of prices. What is also surprising in this paper is that the authors focus solely on one variable as an explanation. What about open source and international comparisons. What about competition between suppliers of the medical products? How does that potentially impact the prices paid? What about leadership and procurement skills and processes? I wanted to know more about the process of purchasing. When does it take place? How are tenders operationalized? What oversight mechanisms are in place?
VERSION 1 -AUTHOR RESPONSE

Reviewer 1
R1.1 -The study examines variations in prices in medical products and the factors that may affect the price variations. It is quite different from the articles I am used to seeing in BMJ Open. I wondered if it would be better to be in a journal in operational research in health care since it seems to be more closely related to hospital logistics. Given the close relationship between prices paid by hospitals and the affordability and accessibility of healthcare we believe that our study is of interest to a wider audience than the operational research community. Given the broad coverage and reader base of BMJ Open we believe it to be a very suitable outlet for this paper. We hope you agree with this reasoning.
R1.2 -The literature review is a bit light. Is there not more evidence on price variations in the hospital sector? Or in the health care sector more generally?
We acknowledge that, in hindsight, out literature overview was a bit light. However, to our knowledge, there really is no research on price variation in the actual prices paid by hospitals for medical products. Existing studies either focus on (international) variation in the listed prices paid for medical products (e.g. Grennan and Swanson 2016) or on (international) price variation for specific medicines (e.g Vogler et al. 2016). Studying listed prices, however, is misleading as large and non-transparent discounts are given to most buyers. Given that the magnitude of these discounts is most often secret (e.g. Lerner et al. 2008 ) studying actual prices paid is difficult to do. Our unique dataset allows us to do just that. To clarify this point we have elaborated our literature review on page 5-6 of out paper.
R1.3 -There is a literature on how to measure variation that is missing. We acknowledge that we should have substantiated better why we measure price variation using the coefficient of variation. Various measures of price variation are discussed in the literature (e.g. Smithson 1982). However, many of these measures are only useful to characterize variations in price over time (Andersen et al. 2003 ) and are therefore not applicable to our study. Moreover, because we want to compare the price variation across different products categories that vary substantially in their absolute price we require a measure of variation that is proportional to the mean (Bland & Altman 1996) . Three main measures are commonly used in such a situation: 1) Gini coefficients, 2) Theil's information theoretic measure, and 3) Coefficients of variation (Smithson 1982) . Of these measures, the coefficient of variation is the most widely used in price variation studies (Bedeian & Mossholder, 2000) . We therefore also adopted this measure of price variation. As a robustness test we also calculated the other two aforementioned measures of price variation and found that they correlate extremely highly with the coefficient of variation (r > 0.98). We have added this discussion and the outcomes of the robustness test to our manuscript on page 10. R.1.4 -In the methods, it would be useful to have more detailed information about how the hospitals were approached (how and who was contacted). One of the authors personally contacted members of the top management of all Dutch hospitals to participate in the survey study. Non-Disclosure Agreements where used whenever desired. The top managers of the various hospitals subsequently asked the purchasers of their hospital to provide the requested data for the survey. This information is now also include on page 8 of our paper.
R1.5 -For the statistical analyses, coefficients of variations are mentioned in the text but there is little information as to these estimates (no table of results with the coefficients). Also, there are various methods to measure variation. The authors do not mention such methods, nor do they seem to apply them. Instead, it appears like the authors ran regressions on the prices of the products. I am not convinced that this is the most appropriate technique. We do not know the distribution of prices for each product, but the data may require some transformation prior to running regressions. I am concerned that the estimates may be biased.
We have added to coefficient of variation to table 2 (see page 12-13). To ensure that the calculation of this indicator is tractable we have also included the mean price and the standard deviation of the price of each product in this table. As the coefficient of variation is the standard deviation divided by the mean the table now includes all information needed for our calculations. With regard to the different measures to calculate price variations we kindly refer to our response to comment R1.3. However, as these diversity measures reflect the variation between prices paid by hospitals for a specific product we can indeed not use these in our regression. As the reviewer rightfully states we run regressions with the prices of the products as the dependent variable. It is important to note that we do so for each product separately to ensure we really estimate price variation between hospitals and not between products. Given that our dependent variable is a scale variable we utilized OLS-regressions. However, because the exact distribution of our dependent variable differs between products (i.e. it is normally distributed for some products but skewed for others) we utilized robust standard errors in all of our models. Moreover, to ensure the robustness of our results we also re-estimated all our models using log-transformed variables. The results of these analyses are identical (in terms of signs and significances of coefficients) as the ones reported in the paper. What kind of models we estimated and why we did so is now explained in more detail in the paper on page 11. R1.6-There is no mention of requesting/obtaining ethics approval for the study. Since we did not include any patients in our survey approval of our local ethics committee was not required. We added this explanation to the 'patient and public involvement' section (see page 8).
R1.7 -The authors have surprising findings in terms of factors affecting variations. Could they try to find explanations for the findings? It seemed light in the discussion. We acknowledge that we focused on one potential explanation for price differences rather than try to find and exhaustive explanation for them. We believe that doing so is a logical first step in unravelling the prices paid by hospitals. The downsize is that we indeed do not know what explains the remaining 74% of the price variation. However, we can say that open source and international comparisons of prices of medical products is rare to due secrecy concerning those prices (Lerner et al. 2008) . As a result such comparisons are based on list prices and not actual prices paid and are therefore rather uninformative. Moreover, these comparisons are mostly made on the country level rather than on the individual hospital level. As such, such comparisons are unlikely to be helpful to hospitals in their negations with medical suppliers.
Competition between medical suppliers could influence the prices paid for a specific product but this competition should exert a general downward pressure on the price and should not lead to price variation between hospitals. Because we study price variation between hospitals for specific medical products such factors should not be of influence. The same holds for patenting and the life cycle of medical products.
Even though it is speculation we believe that the opaque market conditions for medical products results in a situation in which procurement skills and the social capital of purchasers plays a large role. The less transparency there is about prices the more important negotiation skills become. Based on our study we would argue that future studies should try to capture this variation residing in individuals and groups of purchasers. We have added these limitations and recommendations for future research to our paper on page 15-16.
Reviewer 2
R2.1 -The intent of this paper is compelling yet the findings seem too narrow for a fulsome discussion of transparency in medical products and how a lack of transparency can impact variation in prices of the same product. I would recommend a larger contextual discussion of how the Dutch experience may translate into other jurisdictions. Also, what factors contribute to high prices that are not necessarily a result of information asymmetry of prices. At the time of the study the Netherlands had 79 hospitals of which 8 are Academic Hospitals. All of these hospitals are small, especially in an international perspective and compared to the size of the main suppliers of medical products. Nevertheless Dutch hospitals purchase medical products on a decentralized level. This means each hospital is able to negotiate with medical suppliers. There is slight difference between two types of hospital with regard to the way of tendering. Academic hospitals within the Netherlands have to use European tenders to select medical suppliers. General and specialized hospitals can follow the process of European tendering but have more leeway to deviate from this process. The Dutch purchasing context is characterized by a strong focus on three parameters: cost reduction, risk management and service quality. We have added a short description of the Dutch context to page 7-8 of the paper.
The specific of the Dutch context could indeed influence the extent to which our results can be generalized to other jurisdictions. For example, our finding that larger purchasing volumes translate into lower prices implies that countries with more centralized purchasing might have both lower prices and, naturally, less price variation. However, the finding that 74% of the price variation cannot be accounted for implies that there are many, non-economic, factors that play into the price hospitals paid (also see our answer to your next comment). The specific skills or social capital of the purchaser could play a large role, for example, such variation resides mostly at the hospital level and is likely to translate to other jurisdictions as well. We have added a discussion regarding the (limits of) the generalizability of our results to the discussion section of the paper (see page 15-16).
R2.2 -What is also surprising in this paper is that the authors focus solely on one variable as an explanation. What about open source and international comparisons. What about competition between suppliers of the medical products? How does that potentially impact the prices paid? What about leadership and procurement skills and processes? I wanted to know more about the process of purchasing. When does it take place? How are tenders operationalized? What oversight mechanisms are in place?
We acknowledge that we focused on one potential explanation for price differences rather than try to find and exhaustive explanation for them. We believe that doing so is a logical first step in unravelling the prices paid by hospitals. The downsize is that we indeed do not know what explains the remaining 74% of the price variation. However, we can say that open source and international comparisons of prices of medical products is rare to due secrecy concerning those prices (Lerner et al. 2008) . As a result such comparisons are based on list prices and not actual prices paid and are therefore rather uninformative. Moreover, these comparisons are mostly made on the country level rather than on the individual hospital level. As such, such comparisons are unlikely to be helpful to hospitals in their negations with medical suppliers.
Competition between medical suppliers could influence the prices paid for a specific product but this competition should exert a general downward pressure on the price and should not lead to price variation between hospitals. Because we study price variation between hospitals for specific medical products such factors should not be of influence. The same holds for patenting and the life cycle of medical products. Even though it is speculation we believe that the opaque market conditions for medical products results in a situation in which procurement skills and the social capital of purchasers plays a large role. The less transparency there is about prices the more important negotiation skills become. Based on our study we would argue that future studies should try to capture this variation residing in individuals and groups of purchasers. We have added these limitations and recommendations for future research to our paper on page 15-16.
VERSION 2 -REVIEW
REVIEWER
Maude Laberge Universite Laval Faculte de medecine, Operations and Decision Systems REVIEW RETURNED 15-Jan-2020
GENERAL COMMENTS
The authors have made substantial revisions that improve the paper. There are a number of typos and the paper should be undergo a linguistic revision prior to publication.
VERSION 2 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
1. The authors have made substantial revisions that improve the paper. There are a number of typos and the paper should be undergo a linguistic revision prior to publication.
We would like to thank Maud Laberge for the recognition of the revisions made. The paper has undergone another round of linguistic revision by a native speaker to eliminate typos and improve the language.
The native speaker stated that the 'strengths and limitations' section did not pay sufficient attention to the limitations of the paper. Therefore, we have added an extra bullet point, in line with the 'limitations' section that reads: "The dataset only focuses on medical products and, in fact, a limited number of these products".
